Home » Newsletters » BioWorld Science

BioWorld Science

May 7, 1999

View Archived Issues

Genset strengthens obesity/metabolic disorder program

Alexion and Harvard utilize xenotransplantation for Alzheimer's disease

Company Profile: Selective Genetics

Novartis: Operational Review 1998

Company Profile: Eos Biotechnology

Geron acquires Roslin Bio-Med, collaborates with the Roslin Institute

NCI funds phase II trials of Sugen's lead angiogenesis inhibitor

Bigmar and Graminex sign licensing agreement for prostatitis therapy

Protein Design Labs licenses anti-L-selectin antibody to BioNet

CeNeS in-licenses sipatrigine; company pipeline in review

Clinical trials of SuperGen's RFS-2000 expanded to Europe

Novel naturally occurring proteasome inhibitor TMC-95A discovered at Tanabe Seiyaku

Second-generation SERM advances through the Lilly pipeline

Spotlight on treatment of hirsutism

Kissei develops new anticoagulants acting selectively against factor Xa

BE-55051: novel antitumor substance produced by Streptomyces

Substituted morpholines as tachykinin antagonists, 5-HT agonists

Clarion discloses new wound-healing agents in development

New prostaglandin F analogues from P&G targeted for bone disorders, glaucoma

Novel strategy for limiting restenosis targets Gbetagamma signaling

Caspase inhibitor provides neuroprotection in rabbit model of bacterial meningitis

Diatide: Q1 1999 highlights

U.K. regulatory filing for Wyeth Lederle Vaccines' meningococcal C conjugate vaccine

Licensing opportunity from LG Chemical: irreversible HIV protease inhibitor

PDE4 inhibitor XT-44 inhibits bone loss in animal models of osteopenia

La Jolla Pharmaceutical: Q1 1999 highlights

M-5011 compares favorably to indomethacin in model of gouty arthritis

Celgene: Q1 1999 highlights

Phase I trial with Ariad's first Dimerizer Drug successfully completed

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...